| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).
|
|---|---|
| ln Vitro |
Recombinant G551D-CFTR is immediately bound by VRT-532 (15 µM), which modifies its ATPase activity [1].
VRT-532 enhances channel activity in G551D-CFTR and increases the intrinsic ATPase activity of G551D-CFTR. It directly binds to G551D-CFTR in isolated systems, improving channel function and increasing ATPase rate. |
| ln Vivo |
No detailed in vivo activity data is available for this compound. As a CFTR modulator, VRT-532 is expected to improve chloride transport in animal models of cystic fibrosis, but specific in vivo efficacy studies have not been reported.
|
| Enzyme Assay |
The compound's modulation of CFTR activity is assessed in cell-free systems using purified CFTR protein or membrane preparations. ATPase activity assays measure the compound's effect on the intrinsic ATPase activity of G551D-CFTR, while binding studies may be conducted to confirm direct interaction with the mutant channel.
|
| Cell Assay |
VRT-532 is evaluated in cell-based assays using epithelial cells expressing G551D-CFTR mutations. Patch-clamp electrophysiology is used to measure channel activity and assess the compound's ability to enhance chloride conductance, while ATPase activity can also be measured in cellular lysates.
|
| Animal Protocol |
No detailed in vivo animal experimental protocol is available for this compound. For CFTR modulators, typical in vivo studies use CFTR mutant mouse models to assess restoration of chloride transport in airway or intestinal epithelia following compound administration.
|
| ADME/Pharmacokinetics |
No detailed pharmacokinetic data is available for VRT-532. With a molecular weight of 250.30, the compound is expected to have reasonable drug-like properties, but specific PK parameters have not been reported.
|
| Toxicity/Toxicokinetics |
No detailed toxicological data is available for this compound. As a research-grade CFTR modulator, standard preclinical toxicity assessments have not been published.
|
| References |
|
| Additional Infomation |
VRT-532 has a molecular formula of C16H14N2O and a molecular weight of 250.30. The compound is a potent modulator of CFTR that enhances channel activity in G551D-CFTR variants, providing valuable insights into cystic fibrosis mechanisms. It has not advanced to clinical trials and is not FDA-approved.
|
| Molecular Formula |
C16H14N2O
|
|---|---|
| Molecular Weight |
250.29516
|
| Exact Mass |
250.111
|
| CAS # |
38214-71-0
|
| PubChem CID |
781239
|
| Appearance |
White to off-white solid powder
|
| Density |
1.213g/cm3
|
| Boiling Point |
472.9ºC at 760 mmHg
|
| Flash Point |
239.8ºC
|
| Index of Refraction |
1.643
|
| LogP |
3.757
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
291
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
AQWKVJFRGORALM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14N2O/c1-11-7-8-16(19)13(9-11)15-10-14(17-18-15)12-5-3-2-4-6-12/h2-10,19H,1H3,(H,17,18)
|
| Chemical Name |
4-methyl-2-(3-phenyl-1H-pyrazol-5-yl)phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9952 mL | 19.9760 mL | 39.9521 mL | |
| 5 mM | 0.7990 mL | 3.9952 mL | 7.9904 mL | |
| 10 mM | 0.3995 mL | 1.9976 mL | 3.9952 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
